Weight gain associated with valproate in childhood (Q47233621)

12 January 2018

title

Weight gain associated with valproate in childhood (English)

1 reference

12 January 2018

1 reference

Demir E

1

1 reference

12 January 2018

Aysun S

series ordinal

2

1 reference

12 January 2018

publication date

1 May 2000

1 reference

12 January 2018

published in

Pediatric Neurology

1 reference

12 January 2018

volume

22

1 reference

12 January 2018

issue

5

1 reference

12 January 2018

page(s)

361-364

1 reference

12 January 2018

Valproate: an updated review.

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0887-8994%2800%2900133-8

7 January 2021

Established anticonvulsants and treatment of refractory epilepsy

1 reference

https://api.crossref.org/works/10.1016%2FS0887-8994%2800%2900133-8

7 January 2021

Trends in pharmacotherapy of Schizoaffective and bipolar affective disorders: a 5-year naturalistic study

1 reference

https://api.crossref.org/works/10.1016%2FS0887-8994%2800%2900133-8

7 January 2021

Alopecia and mood stabilizers: two case reports

1 reference

https://api.crossref.org/works/10.1016%2FS0887-8994%2800%2900133-8

7 January 2021

Effects of sodium valproate in 100 children with special reference to weight

1 reference

https://api.crossref.org/works/10.1016%2FS0887-8994%2800%2900133-8

7 January 2021

A multicentre comparative trial of sodium valproate and carbamazepine in paediatric epilepsy. The Paediatric EPITEG Collaborative Group

1 reference

https://api.crossref.org/works/10.1016%2FS0887-8994%2800%2900133-8

7 January 2021

Weight gain in epileptic patients during treatment with valproic acid: a retrospective study.

1 reference

https://api.crossref.org/works/10.1016%2FS0887-8994%2800%2900133-8

7 January 2021

A comparison of valproate with carbamazepine for the treatment of complex partial seizures and secondarily generalized tonic-clonic seizures in adults. The Department of Veterans Affairs Epilepsy Cooperative Study No. 264 Group

1 reference

https://api.crossref.org/works/10.1016%2FS0887-8994%2800%2900133-8

7 January 2021

Monotherapy with valproate in primary generalized epilepsies

1 reference

https://api.crossref.org/works/10.1016%2FS0887-8994%2800%2900133-8

7 January 2021

Effects of acute valproic acid administration on carnitine plasma concentrations in epileptic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0887-8994%2800%2900133-8

7 January 2021

l-Carnitine. A preliminary review of its pharmacokinetics, and its therapeutic use in ischaemic cardiac disease and primary and secondary carnitine deficiencies in relationship to its role in fatty acid metabolism

1 reference

https://api.crossref.org/works/10.1016%2FS0887-8994%2800%2900133-8

7 January 2021

Valproate and palmitate binding to serum albumin in valproate-treated patients. Relation to obesity

1 reference

https://api.crossref.org/works/10.1016%2FS0887-8994%2800%2900133-8

7 January 2021

Metabolic changes during treatment with valproate in humans: implication for untoward weight gain

1 reference

https://api.crossref.org/works/10.1016%2FS0887-8994%2800%2900133-8

7 January 2021

Obesity and endocrine disorders in women taking valproate for epilepsy.

1 reference

https://api.crossref.org/works/10.1016%2FS0887-8994%2800%2900133-8

7 January 2021

The effects of sodium valproate on plasma somatostatin and insulin in humans.

1 reference

https://api.crossref.org/works/10.1016%2FS0887-8994%2800%2900133-8

7 January 2021

Sodium valproate: monotherapy and polytherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0887-8994%2800%2900133-8

7 January 2021

The Evaluation of Sodium Valproate in the Treatment of Nelson's Syndrome*

1 reference

https://api.crossref.org/works/10.1016%2FS0887-8994%2800%2900133-8

7 January 2021

A major quantitative trait locus determining serum leptin levels and fat mass is located on human chromosome 2

1 reference

https://api.crossref.org/works/10.1016%2FS0887-8994%2800%2900133-8

7 January 2021

Serum leptin changes in epileptic patients who gain weight after therapy with valproic acid

1 reference

https://api.crossref.org/works/10.1016%2FS0887-8994%2800%2900133-8

7 January 2021

Serum immunoreactive-leptin concentrations in normal-weight and obese humans

1 reference

https://api.crossref.org/works/10.1016%2FS0887-8994%2800%2900133-8

7 January 2021

Leptin levels in human and rodent: Measurement of plasma leptin and ob RNA in obese and weight-reduced subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0887-8994%2800%2900133-8

7 January 2021

The occurrence of C6--C10-dicarboxylic acids in urine from patients and rats treated with dipropylacetate

1 reference

https://api.crossref.org/works/10.1016%2FS0887-8994%2800%2900133-8

7 January 2021

Impaired fatty acid oxidation in children on valproic acid and the effect of L-carnitine

1 reference

https://api.crossref.org/works/10.1016%2FS0887-8994%2800%2900133-8

7 January 2021

Carnitine metabolism in valproate-treated rats: the effect of L-carnitine supplementation

1 reference

https://api.crossref.org/works/10.1016%2FS0887-8994%2800%2900133-8

7 January 2021

Three limitations of the body mass index

1 reference

https://api.crossref.org/works/10.1016%2FS0887-8994%2800%2900133-8

7 January 2021

Carnitine disposition before and during valproate therapy in patients with epilepsy

1 reference

https://api.crossref.org/works/10.1016%2FS0887-8994%2800%2900133-8

7 January 2021

Valproate, lamotrigine, and insulin-mediated risks in women with epilepsy.

1 reference

https://api.crossref.org/works/10.1016%2FS0887-8994%2800%2900133-8

7 January 2021

Valproate causes metabolic disturbance in normal man.

1 reference

https://api.crossref.org/works/10.1016%2FS0887-8994%2800%2900133-8

7 January 2021

Carnitine-dependent changes of metabolic fuel consumption during long-term treatment with valproic acid

1 reference

https://api.crossref.org/works/10.1016%2FS0887-8994%2800%2900133-8

7 January 2021

10.1016/S0887-8994(00)00133-8

Identifiers

DOI

1 reference

12 January 2018

PubMed ID

10913727

1 reference

12 January 2018